Holen Sie sich die Stockscreener-App
1.79
4.28%
-0.08
Schlusskurs vom Vortag:
$1.87
Offen:
$1.78
24-Stunden-Volumen:
22,246
Relative Volume:
1.17
Marktkapitalisierung:
$73.60M
Einnahmen:
$1.88M
Nettoeinkommen (Verlust:
$-8.48M
KGV:
-9.5162
EPS:
-0.1881
Netto-Cashflow:
$-19.13M
1W Leistung:
+0.00%
1M Leistung:
+4.68%
6M Leistung:
+19.33%
1J Leistung:
-19.73%
1-Tages-Spanne:
$1.7201
$1.8799
1-Wochen-Bereich:
$1.6862
$1.92
52-Wochen-Spanne:
$1.175
$2.44
Beyondspring Inc Stock (BYSI) Company Profile
Firmenname
Beyondspring Inc
Sektor
Branche
Telefon
646-528-4184
Adresse
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.79 | 71.96M | 1.88M | -8.48M | -19.13M | -0.1881 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-12-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Eingeleitet | BofA Securities | Buy |
| 2020-12-29 | Eingeleitet | Evercore ISI | Outperform |
| 2020-02-07 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | Nomura | Buy |
| 2019-12-03 | Eingeleitet | William Blair | Outperform |
| 2019-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-30 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-10-25 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Beyondspring Inc Aktie (BYSI) Neueste Nachrichten
BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant - Stock Titan
BeyondSpring Inc.(NasdaqCM: BYSI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
BYSI Q1 2026 Earnings: Narrowing Losses Amid Pipeline Progress, Stock Gains 5.6%Pre-Earnings Drift - dars.gov.et
Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Enterprise value to revenue forward of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI) - TradingView
Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beyondspring Inc (BYSI) Institutional Confidence - TradingKey
Beyondspring Inc (BYSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beyondspring Inc (BYSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BYSI Q1 2026 Earnings: Net Loss Narrows Amid Ongoing Clinical DevelopmentProfitability Analysis - newsline.com
BYSI Q1 2026 Earnings: Pipeline Progress Amidst Pre-Revenue PhaseNet Profit Margin - newsline.com
BeyondSpring Announces Major Leadership Transition and New CEO - The Globe and Mail
BYSI Q1 2026 Earnings: Loss per Share of $0.05, Stock Declines Amid Quiet QuarterEarnings Miss Streak - newsline.com
BeyondSpring names new CEO as founder transitions to chairman role - StreetInsider
BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition - citybiz
BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com - Investing.com South Africa
BeyondSpring Inc. Announces Appointment of Na Li as Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
BeyondSpring names new CEO, CFO as founder shifts to chairman role - Investing.com Nigeria
BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program - Stock Titan
BeyondSpring Inc. Announces Leadership Transition to Enhance Focus on DUBLIN-4 Program and Plinabulin Development - Quiver Quantitative
BeyondSpring: Lan Huang Remains Chairman >BYSI - Moomoo
BeyondSpring Announces Leadership Transition to Deliver - GlobeNewswire
BeyondSpring (BYSI) Shares Promising Phase 2 Findings for Lung C - GuruFocus
BeyondSpring reports phase 2 lung cancer trial results at ASCO - Investing.com
BeyondSpring reports phase 2 lung cancer trial results at ASCO By Investing.com - Investing.com Canada
Lung cancer trial tests drug trio after immunotherapy, 58% alive at 2 years - Stock Titan
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 - GlobeNewswire
BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% DeclineSynthetic Short - The Legal Advocate
BYSI Stock Chart | BEYONDSPRING INC (NASDAQ:BYSI) - ChartMill
BeyondSpring Q1 2026 Earnings: Narrowed Loss Per Share and Positive Stock MovementEarnings Decline Risk - The Legal Advocate
BeyondSpring (BYSI) Q1 2026 Earnings: Narrowing Loss and No Revenue as Clinical-Stage Biotech Advances PipelineProfit Recovery Report - The Legal Advocate
BYSI Q1 2026 Earnings: Narrow Loss and Modest Stock Gain as Pipeline Progress ContinuesInterim Report - The Legal Advocate
BeyondSpring Q1 2026 Earnings: Narrowing Loss Highlights Pipeline Progress Amid Zero RevenueTrending Buy Opportunities - Newser
BeyondSpring Inc. to Present Study 303 on Plinabulin Combination Therapy for NSCLC at ASCO 2026 - Quiver Quantitative
Phase 2 plinabulin combo in resistant NSCLC to appear at 2026 ASCO - Stock Titan
BYSI BeyondSpring beats Q4 EPS estimates by 11 but shares drop 25 on zero revenueValue Pick - Newser
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting - GlobeNewswire
Number of shareholders of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Lan Huang trust gifts 260,582 BeyondSpring (BYSI) shares in Form 4 filing - Stock Titan
BeyondSpring (BYSI) insiders report 14.1% each; trust transfers disclosed - Stock Titan
BeyondSpring Reports Q1 2026 Financial Results: Plinabulin Pipeline Progress and SEED Therapeutics Clinical Update – Minichart - Minichart
BeyondSpring Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) swings to $6.7M net loss as SEED ops weigh - Stock Titan
BeyondSpring Releases Q1 2026 Financial Results - AlphaStreet
BeyondSpring (BYSI) Q1 2026 Results: EPS -$0.05, Revenue $0 -- H - GuruFocus
Finanzdaten der Beyondspring Inc-Aktie (BYSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beyondspring Inc-Aktie (BYSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):